Business Model Breakdown
How Schrodinger Inc Makes Money
SDGR
Market Cap
$1.1B
Annual Revenue
$255M
Profit Margin
-40.6%
Employees
891
The Short Version
Schrödinger Inc. is a life sciences and materials science company that develops and applies its proprietary physics-based computational platform to accelerate drug discovery and materials design. They generate revenue primarily through two segments: software licensing, where they provide their advanced computational tools to pharmaceutical companies, biotech firms, and academic institutions on a subscription basis; and drug discovery collaborations, where they partner with pharmaceutical companies to discover and develop novel drug candidates, earning milestone payments and potential royalties on future sales. This hybrid model leverages the scalability of software with the high-upside potential of drug development.
Where the Revenue Comes From
Software licensing (~60-70% of total revenue - estimate based on typical SaaS growth companies and public filings from training data)
Drug discovery collaborations & milestones (~30-40% of total revenue - estimate based on public filings from training data)
Who buys: Global pharmaceutical companies, biotechnology firms, research institutions, academic labs, and chemical/materials science companies.
Why It Works (Competitive Advantages)
- ✔Proprietary physics-based computational platform with integrated machine learning capabilities.
- ✔Validated platform with successful drug discovery partnerships (e.g., Ajax Therapeutics).
- ✔Extensive IP portfolio in computational chemistry and materials science.
- ✔High switching costs for large enterprise clients adopting their software suite.
Economic Moat: Narrow (Intangible Assets/IP, Switching Costs, Proprietary Technology)
What Our Analysis Says
DVR Score as of June 7, 2026
Schrödinger (SDGR) maintains significant long-term 10x potential, driven by its cutting-edge computational drug discovery platform, strong validation from partnerships like the $2.3B Ajax acquisition, and a large addressable market. The recent Q1 2026 EPS miss and the departure of the Chief Commercial Officer introduce near-term execution and profitability concerns, impacting the momentum and profitability scores. However, the company's reaffirmation of full-year guidance, coupled with robust previous drug discovery revenue growth (124% YoY in Q1 2026) and a strong balance sheet with approximately $406M in cash (as of prior reporting), indicate underlying strength and continued investment in its platform. While the path to profitability remains delayed, the foundational technology and strategic positioning offer substantial upside if operational execution improves and pipeline assets mature. The score has been adjusted downwards to reflect the recent negative operational news and analyst sentiment shifts.